Role of nonnuclear estrogen receptor GPR30 in preganglionic vagal neurons

非核雌激素受体 GPR30 在节前迷走神经元中的作用

• 批准号: 7579612
• 负责人: EUGEN BRAILOIU
• 金额: $ 35万
• 依托单位: TEMPLE UNIV OF THE COMMONWEALTH
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-02-01 至 2013-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7579612
• 关键词: Address; Agonist; Aromatase; Blood Pressure; Blood Pressure Monitors; Bradycardia; Brain Stem; Calcium; Cardiac; Cardiovascular Diseases; Cardiovascular Physiology; Cardiovascular system; Cells; Clinical; Conjugated Equine Estrogens; Development; Estradiol; Estrogen Nuclear Receptor; Estrogen Receptors; Estrogens; Goals; Heart; Heart Rate; Hormone replacement therapy; Hypothalamic structure; Image; Immunohistochemistry; In Vitro; Knowledge; Label; Link; Measurable; Measurement; Mediating; Membrane; Microinjections; Morbidity - disease rate; Neurons; Nuclear Receptors; Pathway interactions; Postmenopause; Premenopause; Progesterone; Property; Rattus; Regulation; Relative (related person); Role; Signal Transduction; Slice; Source; Staining method; Stains; Synapses; Techniques; Testing; Therapeutic; Therapeutic Agents; Urethane; Vagus nerve structure; Woman; cholinergic neuron; design; extracellular; immunocytochemistry; in vivo; insight; interdisciplinary approach; intravenous administration; mortality; neural circuit; novel; nucleus ambiguus; patch clamp; pressure; protective effect; public health relevance; release of sequestered calcium ion into cytoplasm; research study; response

DESCRIPTION (provided by applicant): Cardiovascular disease is a leading cause of morbidity and mortality. Estrogen has been proposed to have a protective effect. In addition to the interaction with two classical nuclear receptors, estrogen activates a non nuclear receptor, GPR30. Our long-term goal is to understand the role of GPR30 in estrogen-mediated neuronal effects. The objective of this application is to determine the role of GPR30 in cardiovascular regulation. Our central hypothesis is that estrogen acting on GPR30 located on neurons of the nucleus ambiguus increases vagal activity to the heart, which may be cardioprotective. Viewed in this context, GPR30 is a potential target for the development of novel cardiovascular therapeutic agents. We will use a multidisciplinary approach including immunohistochemistry, confocal imaging, in vivo monitoring of blood pressure and heart rate, fluorimetric measurement of cytosolic calcium and whole-cell patch-clamp recording to address the following aims. First, localization of GPR30 to cardiac preganglionic neurons of the nucleus ambiguus. Our preliminary results indicate that GPR30 is present in cholinergic neurons of the nucleus ambiguus. We will use retrograde labeling, single and double immunohistochemical staining to identify the presence of GPR30 in cardiac projecting neurons of the nucleus ambiguus and its colocalization with aromatase. Second, measurement of heart rate and blood pressure in response to GPR30 agonists in vivo. Our preliminary results indicate that microinjection of G-1, a specific GPR30 agonist, or 17-estradiol (E2) into the nucleus ambiguus produces bradycardia; the effect was abolished by prior administration of G-36, a GPR30 antagonist. In addition, pilot experiments indicate that intravenous administration of G-1 and E2 decreased mean arterial pressure and heart rate in urethane-anesthetized rats. We will determine the effect of intravenous administration of GPR30 agonists on blood pressure, heart rate and the participation of the vagus nerve in these responses. Third, electrophysiological response of GPR30 activation in single nucleus ambiguus neurons in vitro. Our preliminary results indicate that G-1 excites neurons from nucleus ambiguus. We will determine the effect of GPR30 agonists on membrane properties, evoked and spontaneous synaptic currents from nucleus ambiguus neurons using whole-cell patch-clamp recordings in brainstem slices. Fourth, define the calcium pathways involved in GPR30-mediated neuronal responses. Our preliminary results indicate that activation of GPR30 produces calcium mobilization from external and internal sources in cultured rat hypothalamic neurons; the effect was abolished by pretreatment with G-36. We will determine the calcium pools involved in GPR30 signaling in premotor cardiac vagal neurons. The result of this study will extend our understanding of the mechanisms of action of estrogen on neurons involved in cardiovascular regulation with implications for the development of effective therapeutic approaches in cardiovascular disorders. PUBLIC HEALTH RELEVANCE: We will study the role of a new estrogen receptor in the central control of cardiovascular function. A better understanding of the mechanisms of action of estrogen is critical for the development of new treatments for cardiovascular disease.

描述（由申请人提供）：心血管疾病是发病率和死亡率的主要原因。雌激素被认为有保护作用。除了与两种经典的核受体相互作用外，雌激素还激活非核受体GPR30。我们的长期目标是了解GPR30在雌激素介导的神经元效应中的作用。这项应用的目的是确定GPR30在心血管调节中的作用。我们的中心假设是雌激素作用于位于模棱两可核神经元上的GPR30，增加了对心脏的迷走神经活动，这可能是保护心脏的。在此背景下，GPR30是开发新型心血管治疗剂的潜在靶点。我们将采用多学科方法，包括免疫组织化学、共聚焦成像、血压和心率的体内监测、胞质钙的荧光测量和全细胞膜片钳记录，以解决以下目标。首先，GPR30定位于模棱两可核的心脏神经节前神经元。我们的初步结果表明，GPR30存在于歧义核的胆碱能神经元中。我们将使用逆行标记，单和双免疫组织化学染色来鉴定GPR30在歧义核心脏突出神经元中的存在及其与芳香化酶的共定位。第二，测量体内对GPR30激动剂反应的心率和血压。我们的初步结果表明，微注射G-1，一种特异性GPR30激动剂，或17-雌二醇（E2）进入模棱两可核产生心动过缓；这种作用被先前给予GPR30拮抗剂G-36所消除。此外，初步实验表明，静脉注射G-1和E2可降低尿素麻醉大鼠的平均动脉压和心率。我们将确定静脉注射GPR30激动剂对血压、心率和迷走神经参与这些反应的影响。第三，GPR30在体外单核模糊神经元中激活的电生理反应。我们的初步结果表明，G-1刺激了模棱两可核的神经元。我们将利用全细胞膜片钳记录脑干切片，确定GPR30激动剂对膜特性、诱导和自发突触电流的影响。第四，明确参与gpr30介导的神经元反应的钙通路。我们的初步结果表明，激活GPR30在培养的大鼠下丘脑神经元中产生来自外部和内部来源的钙动员；经G-36预处理后，该作用被消除。我们将确定运动前心脏迷走神经中参与GPR30信号传导的钙池。这项研究的结果将扩展我们对雌激素对参与心血管调节的神经元的作用机制的理解，对开发有效的心血管疾病治疗方法具有重要意义。公共卫生相关性：我们将研究一种新的雌激素受体在心血管功能中枢控制中的作用。更好地了解雌激素的作用机制对于开发新的心血管疾病治疗方法至关重要。